In a few studies on autoantibody against PDLIM1, PDLIM1 was identified as a tumor-associated antigen (TAA) due to inducement of autoantibody response in patients with breast cancer and pancreatic cancer (9, 18). Here, PDLIM1 is linked to pancreatic neoplasm.